HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Jakob R. Izbicki Olaf Thetter Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Passlick, B. Articles by Pantel, K. Search for Related Content PubMed PubMed Citation Articles by Passlick, B. Articles by Pantel, K.

J Thorac Cardiovasc Surg 1995;109:1205-1211
© 1995 Mosby, Inc.

GENERAL THORACIC SURGERY

Immunohistochemical detection of p53 protein is not associated with a poor prognosis in non-small-cell lung cancer

Munich and Gauting, Germany

Supported by the Friedrich-Baur-Stiftung, München, and Dr. Mildred Scheel-Stiftung, Bonn, Germany.

Received for publication March 17, 1994. Accepted for publication Nov. 7, 1994. Address for reprints: B. Passlick, MD, Universitätskrankenhaus Eppendorf, Department of Surgery, Martinistr. 52, 20246 Hamburg, Germany.

Abstract

Immunohistochemical detection of the p53 gene product by monoclonal antibodies has been shown to be associated with a poor clinical outcome in carcinomas of the breast and stomach. Because the prognostic relevance of p53 immunostaining in lung cancer is still under debate, we studied the expression pattern and clinical significance of such staining in 73 patients with operable non-small-cell lung cancer. p53 expression was detected on frozen sections with the use of monoclonal antibody p1801, which recognizes both the wild-type and mutant gene product (alkaline phosphatase-anti-alkaline phosphatase method). A tumor was considered p53 positive if more than 1% of the tumor cells were stained. The p53 expression pattern was compared with clinicopathologic parameters, and analysis of follow-up, based on the data of 65 patients, was done by a log rank test (median observation time, 780 days). Nuclear p53 staining was detected in 33 of 73 non-small-cell lung cancers (45.2%). Comparison with clinicopathologic parameters demonstrated that the p53 protein was detected more frequently in younger patients (younger than 50 years, p= 0.014), whereas no correlation was found with sex, tumor differentiation, tumor histologic type, or TNM stage. Surprisingly, follow-up analysis revealed that p53 staining was associated with an increased rate of disease-free survival, especially in patients with early stage tumor disease (p= 0.004) and in male patients (p= 0.023). Counter to previous studies in other solid tumors, immunocytochemical detection of p53 expression does not predict a poor clinical outcome in non-small-cell lung cancer. In early-stage lung cancer it might be associated with an improved disease-free survival, which suggests that the majority of the detected protein inherits the wild-type tumor suppressor function. (J THORACCARDIOVASCSURG1995;109:1205-11)

This article has been cited by other articles:

				C. Gebitekin, A. S Bayram, B. Tunca, and S. A Balaban Clinical Significance of p53 Gene Mutation in T1-2N0 Non-Small Cell Lung Cancer Asian Cardiovasc Thorac Ann, February 1, 2007; 15(1): 35 - 38. [Abstract] [Full Text] [PDF]

				J. Laudanski, W. Niklinska, T. Burzykowski, L. Chyczewski, and J. Niklinski Prognostic significance of p53 and bcl-2 abnormalities in operable non-small cell lung cancer Eur. Respir. J., April 1, 2001; 17(4): 660 - 666. [Abstract] [Full Text] [PDF]

				A. Ohgami, T. Mitsudomi, K. Sugio, T. Tsuda, T. Oyama, K. Nishida, T. Osaki, and K. Yasumoto Micrometastatic Tumor Cells in the Bone Marrow of Patients With Non-Small Cell Lung Cancer Ann. Thorac. Surg., August 1, 1997; 64(2): 363 - 367. [Abstract] [Full Text]